Get started
RAPHAEL PHARMACEUTICAL INC.RAPHAEL PHARMACEUTICAL INC.RAPHAEL PHARMACEUTICAL INC.

RAPHAEL PHARMACEUTICAL INC.

No trades
OverviewFinancialsNewsCommunityTechnicalsSeasonals

Fundamentals and stats

Key facts

Market capitalization—
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)—
Founded—
Employees (FY)—
CEO—
Website—
About

Raphael Pharmaceutical, Inc. is a clinical-stage biotechnology company. It is focused on providing a novel cannabinoid-based research platform for the treatment of inflammatory diseases. The firm’s product candidate, HPC1, is a cannabinoid formulation developed for the treatment of rheumatoid arthritis. The company was founded in May 2007 and is headquartered in Tel Aviv, Israel.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends
RAPH has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company